ArriVent Biopharma amendment: Sofinnova entities and two managing members report beneficial ownership of 1,696,752 shares of Common Stock, representing 4.1% of the class.
The filing amends and restates a prior statement filed on November 12, 2024 and clarifies voting and dispositive powers among SVP XI, SM XI LP, SM XI LLC, Dr. James I. Healy and Dr. Maha Katabi.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
ArriVent Biopharma, Inc.
(Name of Issuer)
Common Stock, $0.0001 Par Value per Share
(Title of Class of Securities)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Sofinnova Venture Partners XI, L.P. ("SVP XI")
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,696,752.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,696,752.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,696,752.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Note to Row 5: 1,696,752 shares, except that Sofinnova Management XI, L.P. ("SM XI LP"), the general partner of SVP XI, may be deemed to have sole voting power, Sofinnova Management XI, L.L.C. ("SM XI LLC"), the general partner of SM XI LP, may be deemed to have sole voting power, and Dr. James I. Healy ("Healy") and Dr. Maha Katabi ("Katabi"), the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.
Note to Row 6: See response to row 5.
Note to Row 7: 1,696,752 shares, except that SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.
Note to Row 8: See response to row 7.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Sofinnova Management XI, L.P. ("SM XI LP")
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,696,752.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,696,752.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,696,752.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Note to Row 5: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole voting power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.
Note to Row 6: See response to row 5.
Note to Row 7: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.
Note to Row 8: See response to row 7.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Sofinnova Management XI, L.L.C. ("SM XI LLC")
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,696,752.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,696,752.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,696,752.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Note to Row 5: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole voting power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.
Note to Row 6: See response to row 5.
Note to Row 7: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.
Note to Row 8: See response to row 7.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Dr. James I. Healy ("Healy")
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,696,752.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,696,752.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,696,752.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Note to Row 6: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power over the shares owned by SVP XI, and Healy, a managing member of SM XI LLC, and a director of the Issuer, may be deemed to have shared power to vote these shares.
Note to Row 8: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy, a managing member of SM XI LLC, and a director of the Issuer, may be deemed to have shared power to dispose of these shares.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Dr. Maha Katabi ("Katabi")
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CANADA (FEDERAL LEVEL)
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,696,752.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,696,752.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,696,752.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Note to Row 6: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power over the shares owned by SVP XI, and Katabi, a managing member of SM XI LLC, may be deemed to have shared power to vote these shares.
Note to Row 8: 1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Katabi, a managing member of SM XI LLC, may be deemed to have shared dispositive power over these shares.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ArriVent Biopharma, Inc.
(b)
Address of issuer's principal executive offices:
18 Campus Boulevard Suite 100, Newtown Square, PA 19073
Item 2.
(a)
Name of person filing:
This Statement is filed by Sofinnova Venture Partners XI, L.P. ("SVP XI"), Sofinnova Management XI, L.P. ("SM XI LP"), Sofinnova Management XI, L.L.C. ("SM XI LLC"), Dr. James I. Healy ("Healy") and Dr. Maha Katabi ("Katabi"). The foregoing entities and individuals are collectively referred to as the "Reporting Persons."
This Amendment No. 1 to Schedule 13G (this "Amendment") amends and restates in its entirety the Statement on Schedule 13G that was initially filed on November 12, 2024 (the "Original Schedule 13G"), on behalf of the Reporting Persons, in respect of shares of Common Stock, $0.0001 Par Value per Share ("Common Stock"), of ArriVent Biopharma, Inc. (the "Issuer").
(b)
Address or principal business office or, if none, residence:
The address for each of the Reporting Persons is:
c/o Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 3, Suite 150
Menlo Park, CA 94025
(c)
Citizenship:
Each of SVP XI and SM XI LP is a Delaware limited partnership. SM XI LLC is a Delaware limited liability company. Healy is a U.S. citizen. Katabi is a Canadian citizen.
(d)
Title of class of securities:
Common Stock, $0.0001 Par Value per Share
(e)
CUSIP No.:
04272N102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See Row 9 of cover page for each Reporting Person.*
(b)
Percent of class:
See Row 11 of cover page for each Reporting Person.*
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Row 5 of cover page for each Reporting Person.*
(ii) Shared power to vote or to direct the vote:
See Row 6 of cover page for each Reporting Person.*
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of cover page for each Reporting Person.*
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for each Reporting Person.
* Except to the extent of a Reporting Person's pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Under certain circumstances set forth in the limited partnership agreement of each of SVP XI and SM XI LP and the limited liability company agreement of SM XI LLC, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or member, as the case may be.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sofinnova Venture Partners XI, L.P. ("SVP XI")
Signature:
/s/ Nathalie Auber
Name/Title:
Nathalie Auber, Attorney-in-Fact
Date:
03/05/2026
Sofinnova Management XI, L.P. ("SM XI LP")
Signature:
/s/ Nathalie Auber
Name/Title:
Nathalie Auber, Attorney-in-Fact
Date:
03/05/2026
Sofinnova Management XI, L.L.C. ("SM XI LLC")
Signature:
/s/ Nathalie Auber
Name/Title:
Nathalie Auber, Attorney-in-Fact
Date:
03/05/2026
Dr. James I. Healy ("Healy")
Signature:
/s/ Nathalie Auber
Name/Title:
Nathalie Auber, Attorney-in-Fact
Date:
03/05/2026
Dr. Maha Katabi ("Katabi")
Signature:
/s/ Nathalie Auber
Name/Title:
Nathalie Auber, Attorney-in-Fact
Date:
03/05/2026
Comments accompanying signature: *Executed pursuant to a Power of Attorney already on file with the appropriate agencies.
What ownership does Sofinnova report in ArriVent Biopharma (AVBP)?
Sofinnova reports beneficial ownership of 1,696,752 shares, or 4.1%. The Schedule 13G/A shows those shares are owned directly by Sofinnova Venture Partners XI, L.P., with related entities and individuals reporting voting/dispositive arrangements.
Who are the reporting persons on the AVBP Schedule 13G/A amendment?
The reporting persons are SVP XI, SM XI LP, SM XI LLC, Dr. James I. Healy and Dr. Maha Katabi. The filing states the entities and individuals filed collectively and executed the amendment via attorney-in-fact.
Does the filing state any change in control or transfer of AVBP shares?
No transfer or change-in-control is stated; the filing amends and restates a prior statement. It clarifies allocation of voting and dispositive power among the Sofinnova entities and named individuals.
How is voting and dispositive power allocated for the reported AVBP shares?
The filing attributes sole voting and dispositive power to SVP XI (1,696,752 shares), with SM XI LP and SM XI LLC potentially deemed to have such powers. Healy and Katabi may be deemed to share those powers as managing members.
When was this Schedule 13G/A amendment executed for AVBP?
The amendment is dated March 5, 2026. It amends the original statement filed on November 12, 2024 and is signed by an attorney-in-fact on behalf of the reporting persons.
